This seems a little low value. It needs to be shorter for one. I don't really get their point about Color genomics. This company offers DTC a product which genetics labs already do everywhere. There are a lot of available resources for interpreting the results of BRCA1&2 testing. It seems silly to claim they 'have a moat'. They just started at the moment that Myriad Genetics lost its monopoly on the gene. They are offering cheap testing which must be subsidised by venture funding - I know this because Color charges less for the test than not-for-profit companies.